Maze Therapeutics CSBO Sells: Reading Insider Moves
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Discover why indices rise or fall, examining earnings, macro data, and policy factors that shape broad market direction.
21,369 articlesWhen a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Cognex is navigating a world of AI-powered machine vision in manufacturing. This article breaks down the Q1 2026 resu...
Investors are watching Crinetics' Q1 2026 results for clues on milestones, cash runway, and partnerships. This guide ...
As investors eye ngvc 2026, this guide breaks down the factors driving NGVC’s earnings, from store growth to margins ...
CFOs and boards are confronting a pivotal moment: how well they govern AI agents to protect value and manage risk. Th...
A tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
Accredited investors can now access a portfolio of 25,000+ multifamily units via Lightstone's private-market platform...
Analysts watch Verrica's 2026 earnings for clues on VP-102 sales, cash runway, and pipeline progress. This guide brea...
NVIDIA remains dominant in AI hardware, but a software-first AI stock is delivering bigger gains. Learn why investors...
The AI era has investors torn between memory stocks and dedicated AI chip leaders. This guide breaks down how to deci...
A notable fund just built a sizable position in Appian as AI driven automation accelerates. This article breaks down ...
A $1,000 stake can still grow, even in shaky markets. This guide shows how to identify the smartest stock with $1,000...